MedTrace Logo

Metformin Plus Sorafenib for Advanced HCC

NCT02672488 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2016-02-03

No results posted yet for this study

Summary

Metformin is a widely used oral drug for type 2 diabetes and its antitumor effects have got much more attentions recently. It has been shown that metformin exerts anti-cancer activities in several cancers, including primary liver cancer. In this phase II study, safety and efficacy of the combination of metformin and sorafenib will be evaluated in patients with advanced hepatocellular carcinoma.

Conditions

Interventions

DRUG

Sorafenib

Standard treatment for advanced HCC

DRUG

Metformin

To evaluate the safety and efficacy of the combined treatment of Metformin and Sorafenib for advanced HCC

Sponsors & Collaborators

  • First Affiliated Hospital of Harbin Medical University

    collaborator OTHER

  • Harbin Medical University

    collaborator OTHER

  • Liaoning Cancer Hospital & Institute

    collaborator OTHER

  • Shanghai Zhongshan Hospital

    collaborator OTHER

  • Fudan University

    collaborator OTHER

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Principal Investigators

  • Ti Zhang, MD · Tianjin Medical University Cancer Institute and Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2017-12-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02672488 on ClinicalTrials.gov